VP & GM, Clinical Genomics, QIAGEN Bioinformatics
Sean Scott is the VP and GM, Clinical Genomics for QIAGEN. Sean is responsible for QIAGEN’s Clinical Genomics product portfolio offering serving the needs of molecular diagnostics and molecular pathology testing laboratories related to NGS-based genetic test interpretation and reporting across germline and somatic test indications. Sean recently led the development of QIAGEN new Ingenuity Clinical Decision Support platform, an instrument platform, assay and pipeline agnostic solution, that enables clinical labs to scale annotation, interpretation and reporting of their screening, diagnostic and monitoring test offerings. Sean joined QIAGEN in 2013 through QIAGEN’s acquisition of Ingenuity Systems where he, prior to QIAGEN, spent six years as SVP, Global Commercial Operations and SVP, Corporate Development for Ingenuity Systems.
Scaling NGS Test Interpretation and Reporting In Oncology
The interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limitingfactor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefly demonstrate how QIAGEN’s new Ingenuity®Clinical Decision Support platform helps these labs to scale their testing services and improve the actionability of reporting through a comprehensive levels of evidence based approach and CLIA-Cap compliant reporting guidelines.